The Department of Health – Abu Dhabi (DoH) has teamed up with pharmaceutical company Novartis to strengthen collaboration in genomics research, scientific capacity building and advanced therapies.
The partnership aims to combine Abu Dhabi's growing expertise in genomics with Novartis' global scientific experience to support research, build local capabilities and improve access to innovative treatments.
The move builds on the success of the Emirati Genome Programme, which has sequenced more than 900,000 genomes, creating new opportunities for personalised healthcare and disease prevention.
Health officials say the collaboration will help turn genomic research into real-world healthcare solutions, benefiting patients in the UAE and beyond.
"Abu Dhabi has established one of the world's most comprehensive population genomics programmes, creating new opportunities to better understand disease, improve prevention and accelerate the development of more personalised approaches to care," said Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the DoH.
"This collaboration with Novartis strengthens an ecosystem that already brings together genomics, research, healthcare delivery and innovation within a single connected environment," she added.
The MoU was signed during the Department of Health – Abu Dhabi's (DoH) visit to the Novartis Biomedical Research site in San Diego, alongside the BIO International Convention 2026.
The signing builds on the longstanding relationship between DoH and Novartis across multiple areas, including clinical research, health technology assessment, and policy engagement in innovative treatment areas.
"By combining Abu Dhabi’s ambitious vision for healthcare innovation with Novartis’ global scientific expertise, we have an opportunity to support advances in genomics research, scientific capability building, and the future of precision medicine. We look forward to exploring initiatives that can contribute to better health outcomes and help address the evolving needs of patients in the UAE," said Mohamed Ezz Eldin, Head of Novartis GCC Cluster.
H.H. Sheikh Hamdan honours winners of inaugural Dubai-it Award
Ras Al Khaimah reopens several beaches to the public
Abu Dhabi expands EV charging points in public parking areas
Dubai student card unlocks public transport savings, global discounts
UAE lifts visa restrictions on Ugandan nationals
Dr Gargash highlights UAE's 'constructive role' in Russia-Ukraine-US trilateral talks
Ras Al Khaimah Ruler leads UAE delegation at COP31
Dubai to reward residents with AED 2,500 for naming community parks
ADNOC L&S vessel sustains damage following attack
H.H. Sheikh Khaled, H.H. Sheikh Hamdan discuss key national priorities
Sheikh Abdullah attends third round of Russia-Ukraine-US trilateral talks
UAE completes critical design review of 'Sirb-1' satellite
UAE conditionally approves new use of Ultomiris for kidney disease patients
H.H. Sheikh Hamdan approves Dubai Metro extension to Al Maktoum Airport
UAE Year Of Award celebrates stronger families, community values
UAE President highlights nation's resilience during 'recent challenges'
H.H. Sheikh Khaled approves second package of Emirati Family Growth Programme
Sharjah approves housing support for 1,100 families
H.H. Sheikh Mohammed directs tents for 50,000 Gazans facing harsh weather
UAE postpones vehicle licensing limit for residents
